medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2021, Number 3

<< Back Next >>

Rev Nefrol Dial Traspl 2021; 41 (3)

Idiopathic hypercalciuria: diagnosis, classification and treatment

Rodolfo SF, del Valle EE, Rojas PPA

Language: Spanish
References: 36
Page: 184-191
PDF size: 171.85 Kb.


ABSTRACT

Introduction: Idiopathic hypercalciuria is defined as urine calcium excretion greater than 220 mg/day in women and 300 mg/day in men, or greater than 4 mg/kg under regular dietary conditions. Objective: The aim of this study is to review the diagnosis, classification, and treatment of hypercalciuric patients with renal lithiasis. Methods: We enrolled 250 patients suffering from renal lithiasis and idiopathic hypercalciuria and 80 healthy subjects as control group. Lab tests were performed to diagnose renal lithiasis. Results: Although the 24- hour urine test is the gold standard to determine calciuria, in this study we propose considering the Ca/Kg ›4 mg/Kg ratio or an index of ›140 mg of Ca per gram urine creatinine. Regarding the different types of hypercalciuria, after following a strict diet, subjects were divided into two groups: diet-dependent and diet-independent hypercalciuria. Concerning the treatment, we suggest diuretic therapy to achieve a urine output of 2-2.5 liters per day. In the case of subjects with diet-dependent hypercalciuria, we advise an intake of 600-800 mg of calcium and a moderate reduction in animal protein and salt intake. In cases of non-response to treatment in subjects with diet-dependent hypercalciuria, thiazides, chlorthalidone, indapamide and, in some cases, bisphosphonates may help control hypercalciuria with a lower risk of lithiasis recurrence and healthier bones. Conclusions: We believe it is important to consider not only the methods to diagnose hypercalciuria but also its classification to provide a better treatment.


REFERENCES

  1. Worcester EM, Coe FL. New insights into thepathogenesis of idiopathic hypercalciuria. SeminNephrol. 2008;28(2):120-32. doi: 10.1016/j.semnephrol.2008.01.005.

  2. del Valle EE, Spivacow FR, Zanchetta JR. Alteracionesmetabólicas en 2612 pacientes con litiasis renal.Medicina (B Aires). 1999;59(5/1):417-22.

  3. Coe FL, Evan A, Worcester E. Kidney stone disease.J Clin Invest. 2005;115(10):2598-608. doi: 10.1172/JCI26662.

  4. Lauderdale DS, Thisted RA, Wen M, FavusMJ. Bone mineral density and fracture amongprevalent kidney stone cases in the Third NationalHealth and Nutrition Examination Survey. J BoneMiner Res. 2001;16(10):1893-8. doi: 10.1359/jbmr.2001.16.10.1893.

  5. Melton LJ 3rd, Crowson CS, Khosla S, WilsonDM, O’Fallon WM. Fracture risk among patientswith urolithiasis: a population-based cohort study.Kidney Int. 1998;53(2):459-64. doi: 10.1046/j.1523-1755.1998.00779.x.

  6. Vezzoli G, Soldati L, Gambaro G. Hypercalciuriarevisited: one or many conditions? Pediatr Nephrol.2008;23(4):503-6. doi: 10.1007/s00467-007-0574-3.

  7. Giannini S, Nobile M, Dalle Carbonare L, Lodetti MG,Sella S, Vittadello G, et al. Hypercalciuria is a commonand important finding in postmenopausal women withosteoporosis. Eur J Endocrinol. 2003;149(3):209-13.doi: 10.1530/eje.0.1490209.

  8. Coe FL, Parks JH, Asplin JR. The pathogenesisand treatment of kidney stones. N Engl JMed. 1992;327(16):1141-52. doi: 10.1056/NEJM199210153271607.

  9. Manz F, Kehrt R, Lausen B, Merkel A. Urinary calciumexcretion in healthy childrenand adolescents. Pediatr Nephrol. 1999;13(9):894-9. doi: 10.1007/s004670050723.

  10. Hodgkinson A, Pyrah LN. The urinary excretionof calcium and inorganic phosphate in 344 patientswith calcium stone of renal origin. Br J Surg.1958;46(195):10-8. doi: 10.1002/bjs.18004619504.

  11. Worcester EM, Coe FL. Evidence for altered renaltubule function in idiopathic calcium stone formers.Urol Res. 2010;38(4):263-9. doi: 10.1007/s00240-010-0299-9.

  12. Coe FL, Parks JH. Nephrolithiasis: Pathogenesisand treatment. 2nd ed. Chicago: Year Book MedicalPublishers,1998, pp. 109-10.

  13. Spivacow FR, Pailler M, Martínez P. HipercalciuriaIdiopática: ¿se pueden evitar los diuréticos? Medicina (BAires). 2019;79(6):477-82.

  14. Pak CY. Medical stone management: 35 years ofadvances. J Urol. 2008;180(3):813-9. doi: 10.1016/j.juro.2008.05.048.

  15. Bataille P, Fardellone P, Ghazali A, Cayrolle G, HottelartC, Achard JM, et al. Pathophysiology and treatmentof idiopathic hypercalciuria. Curr Opin Rheumatol.1998;10(4):373-88. doi: 10.1097/00002281-199807000-00017.

  16. McDonald MW, Stoller ML. Urinary stone disease:a practical guide to metabolic evaluation. Geriatrics.1997;52(5):38-40, 49-52, 55-6.

  17. Ghazali S, Barratt TM. Urinary excretion ofcalcium and magnesium in children. Arch Dis Child.1974;49(2):97-101. doi: 10.1136/adc.49.2.97.

  18. Tekin A, Tekgul S, Atsu N, Sahin A, Ozen H,Bakkaloglu M. A study of the etiology of idiopathiccalcium urolithiasis in children: hypocitruria is themost important risk factor. J Urol. 2000;164(1):162-5.

  19. Nordin BE. Assessment of calcium excretionfrom the urinary calcium/creatinine ratio. Lancet.1959;2(7099):368-71. doi: 10.1016/s0140-6736(59)91635-6.

  20. Coe FL, Favus MJ, Crockett T, Strauss AL, ParksJH, Porat A, et al. Effects of low-calcium diet onurine calcium excretion, parathyroid function,and serum 1,25(OH)2D3 levels in patients withidiopathic hypercalciuria and in normal subjects.Am J Med. 1982;72(1):25-32. doi: 10.1016/0002-9343(82)90567-8.

  21. Giusti A, Barone A, Pioli G, Girasole G, Siccardi V,Palummeri E, et al. Alendronate and indapamide aloneor in combination in the management of hypercalciuriaassociated with osteoporosis: a randomized controlledtrial of two drugs and three treatments. Nephrol DialTransplant. 2009;24(5):1472-7. doi: 10.1093/ndt/gfn690.

  22. Lerolle N, Lantz B, Paillard F, Gattegno B, FlahaultA, Ronco P, et al. Risk factors for nephrolithiasis inpatients with familial idiopathic hypercalciuria. AmJ Med. 2002;113(2):99-103. doi: 10.1016/s0002-9343(02)01152-x.

  23. Bihl G, Meyers A. Recurrent renal stone diseaseadvancesin pathogenesis and clinical management.Lancet. 2001;358(9282):651-6. doi: 10.1016/S0140-6736(01)05782-8.

  24. Weisinger JR, Alonzo E, Machado C, Carlini R,Martinis R, Paz-Martinez V, et al. Papel del huesoen la fisiopatología de la hipercalciuria idiopática.Medicina (B. Aires). 1997;57(supl. 1):45-8.

  25. Coe FL, Parks JH. New insights into thepathophysiology and treatment of nephrolithiasis: newresearch venues. J Bone Miner Res. 1997;12(4):522-33.doi: 10.1359/jbmr.1997.12.4.522.

  26. Weisinger JR, Alonzo E, Bellorín-Font E, Blasini AM,Rodríguez MA, Paz-Martínez V, et al. Possible roleof cytokines on the bone mineral loss in idiopathichypercalciuria. Kidney Int. 1996;49(1):244-50. doi:10.1038/ki.1996.34.

  27. Farías ML, Delgado AG, Rosenthal D, Vieira JG,Kasamatsu T, Lazarevitch MJ, et al. The cause ofmaintained hypercalciuria after the surgical cure ofprimary hyperparathyroidism is a defect in renal calciumreabsorption. J Endocrinol Invest. 1996;19(1):12-20.doi: 10.1007/BF03347852.

  28. Breslau NA. Pathogenesis and management ofhypercalciuric nephrolithiasis. Miner Electrolyte Metab.1994;20(6):328-39.

  29. Pacifici R. Idiopathic hypercalciuria and osteoporosis:distinct clinical manifestations of increased cytokineinducedbone resorption? J Clin Endocrinol Metab.1997;82(1):29-31. doi: 10.1210/jcem.82.1.3706.

  30. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E,Nakamura Y, et al. IL-6 is produced by osteoblastsand induces bone resorption. J Immunol.1990;145(10):3297-303.

  31. Passeri G, Girasole G, Jilka RL, Manolagas SC.Increased interleukin-6 production by murine bonemarrow and bone cells after estrogen withdrawal.Endocrinology. 1993;133(2):822-8. doi: 10.1210/endo.133.2.8393776.

  32. Costanzo LS, Weiner IM. On the hypocalciuric actionof chlorothiazide. J Clin Invest. 1974;54(3):628-37.doi: 10.1172/JCI107800.

  33. Jang HR, Kim S, Heo NJ, Lee JH, Kim HS, NielsenS, et al. Effects of thiazide on the expression ofTRPV5, calbindin-D28K, and sodium transportersin hypercalciuric rats. J Korean Med Sci. 2009;24Suppl(Suppl 1):S161-9. doi: 10.3346/jkms.2009.24.S1.S161.

  34. Spivacow FR, Negri AL, del Valle E. Efecto a largoplazo de tiazidas sobre la masa ósea en mujeres connefrolitiasis hipercalciúrica. Rev Nefrol Dial Traspl.2013;33(4):180-7.

  35. Zanchetta JR, Rodríguez G, Negri AL, del ValleE, Spivacow FR. Bone mineral density in patientswith hypercalciuric nephrolithiasis. Nephron.1996;73(4):557-60. doi: 10.1159/000189140.

  36. Ceylan K, Topal C, Erkoc R, Sayarlioglu H, Can S,Yilmaz Y, et al. Effect of indapamide on urinary calciumexcretion in patients with and without urinary stonedisease. Ann Pharmacother. 2005;39(6):1034-8. doi:10.1345/aph.1E544.




2020     |     www.medigraphic.com